HELP

NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Amir Inamdar, Helus Pharma's Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference taking place June 15-16, 2026. The fireside chat will be available on demand beginning on Monday, June 15 at 7:00 a.m. EDT. To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma's investor relations website. About Helus Phar

6-K - CYBIN INC. (0001833141) (Filer)

Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT NEW YORK and TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Eric So, Helus Pharma's Interim Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, taking place June 2-4, 2026. The fireside chat will be webcast live on Thursday, June 4, 2026, at 2:35 p.m. EDT. To register for the webcast, click here. A replay will be available on the Events & Present

6-K - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

Eric So, Interim CEO, to appear on panel entitled "The Next Wave of Health Innovation," on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Eric So, Helus Pharma's Interim Chief Executive Officer, will be speaking at the 29th Annual Milken Institute Global Conference on a panel entitled "The Next Wave of Health Innovation." The Conference will take place May 3-6, 2026, at The Beverly Hilton & Waldorf Astoria in Los Angeles, and the panel will be held on Monday, May 4, 2026, at 2:30

6-K - CYBIN INC. (0001833141) (Filer)

Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced a collaboration with TARA Mind, which works with Veterans Exploring Treatment Solutions ("VETS") to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program for Major Depressive Disorder ("MDD"), while expanding mental health aw

6-K - CYBIN INC. (0001833141) (Filer)

Addition of globally recognized leaders in translational science and clinical development as the Company advances its pipeline towards key inflection points NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the addition of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board. Helus Pharma's Scientific Advisory Board supports the Company's commitment to advancing its pipeline through disciplined drug development and scientific rigor. The addition of Dr. Langer and Dr. Brannan re

SCHEDULE 13G/A - CYBIN INC. (0001833141) (Subject)

6-K - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic treatments. "The Executive Order reflects growing recognition of the urgent need for new treatment options in serious mental health conditions and the importance of advancing innovative therapies through rigorous, research-based development," said Eric So, Interim Chief Executive Officer of Helus Pharma. "Policy momentum is meaningful,

This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Michael Cola is stepping down as Chief Executive Officer, effective immediately, at the request of the Board of Directors. The Board has appointed Co-founder and Executive Chairman Eric So to resume his role as I

6-K - CYBIN INC. (0001833141) (Filer)

Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs, effective immediately. Dr. Kramer joins Helus with more than two decades of experience leading medical affairs strategy across neuroscience programs, including global launch readiness, eviden

TD Cowen initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $8.00

SCHEDULE 13G - CYBIN INC. (0001833141) (Subject)

SCHEDULE 13G - CYBIN INC. (0001833141) (Subject)

6-K - CYBIN INC. (0001833141) (Filer)

Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company advances its novel clinical pipeline NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Jill Conwell as Chief People Officer, effective immediately. Conwell brings more than two decades of leadership experience in the life sciences industry, with expertise spanning organizational st

Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), a

GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions NEW YORK, March 5, 2026 /CNW/ -- Market News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news for millions of people dealing with constant worry and stress. Traditional medications like anti-anxiety drugs and antidepressants still play a big role, but therapy options such as cognitive-behavioral therapy and mindfulness techniques are also helping people manage symptoms without relying only on medication. Digital mental health tools and telehealth visits are making treatment easier to access, especially f

6-K - CYBIN INC. (0001833141) (Filer)